Lancet Neurology

Article	Citations
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	2267
Neurological associations of COVID-19	1439
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series	928
Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?	745
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts	658
Challenges in the diagnosis of Parkinson's disease	477
Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches	398
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches	397
Advances and challenges in stroke rehabilitation	395
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group	392
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation	360
Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues	304
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis	301
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial	273
Myelin-oligodendrocyte glycoprotein antibody-associated disease	262
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria	260
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias	258
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial	224
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study	219
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study	219
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study	217
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial	216
New insights into atypical Alzheimer's disease in the era of biomarkers	216
Interpretation of risk loci from genome-wide association studies of Alzheimer's disease	210
Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia	206

Traumatic brain injury: progress and challenges in prevention, clinical care, and research	204
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study	193
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial	193
Remyelination in multiple sclerosis: from basic science to clinical translation	190
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial	182
Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study	177
Long-term unsupervised mobility assessment in movement disorders	176
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study	174
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study	174
The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data	168
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-cont	160
A case of probable Parkinson's disease after SARS-CoV-2 infection	159
An Italian programme for COVID-19 infection in multiple sclerosis	157
Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease	150
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study	145
The neuropsychiatry of Parkinson's disease: advances and challenges	144
Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation	143
Progress towards therapies for disease modification in Parkinson's disease	139
30 years of second-generation antiseizure medications: impact and future perspectives	137
Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial	136
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials	133
Monogenic variants in dystonia: an exome-wide sequencing study	132
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis	130
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis	123
Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts	119
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial	119
Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis	119
Multiple sclerosis progression: time for a new mechanism-driven framework	117
Post-viral effects of COVID-19 in the olfactory system and their implications	117
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder	117
PET imaging of neuroinflammation in neurological disorders	116
Functional neurological disorder: new subtypes and shared mechanisms	114
COVID-19 related stroke in young individuals	114
Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial	111
Evidence-based support for autistic people across the lifespan: maximising potential, minimising barriers, and optimising the person–environment fit	110
Neuromodulation in epilepsy: state-of-the-art approved therapies	109
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial	108
Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study	107
Medical management with interventional therapy versus medical management alone for unruptured brain arteriovenous malformations (ARUBA): final follow-up of a multicentre, non-blinded, randomised contr	106
Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study	105
Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial	105
Initiation of pharmacological therapy in Parkinson's disease: when, why, and how	105
Moyamoya disease: diagnosis and interventions	103
Integrated and patient-centred management of Parkinson's disease: a network model for reshaping chronic neurological care	102
Forecasting seizure risk in adults with focal epilepsy: a development and validation study	100
Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies	99
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled,	98
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities	98
Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis	98
Neuroimaging standards for research into small vessel disease—advances since 2013	97

Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies	96
Alzheimer's disease associated with Down syndrome: a genetic form of dementia	96
SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy	95
Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances	95
Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective	95
Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study	94
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study	94
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials	92
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial	92
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment	91
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial	90
Brain injury after cardiac arrest: from prognostication of comatose patients to rehabilitation	89
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial	89
Ageing without dementia: can stimulating psychosocial and lifestyle experiences make a difference?	89
Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial	87
Advances in oral immunomodulating therapies in relapsing multiple sclerosis	87
Mitochondrial disease in adults: recent advances and future promise	85
Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled st	85
Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study	85
New therapies for neuromyelitis optica spectrum disorder	84
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial	84
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial	83
Clinical characteristics and outcomes in patients with traumatic brain injury in China: a prospective, multicentre, longitudinal, observational study	83
Epilepsy in China: major progress in the past two decades	83
Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials	82
A biological classification of Huntington's disease: the Integrated Staging System	80
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)	77
Diagnosis and classification of optic neuritis	75
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders	75
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial	74
Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study	73
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study	72
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches	70
Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial	69
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations	67
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial	67
Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study	66
Amantadine in the treatment of Parkinson's disease and other movement disorders	66
Menstrual migraine: a distinct disorder needing greater recognition	65
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial	65
Aspirin versus anticoagulation in cervical artery dissection (TREAT-CAD): an open-label, randomised, non-inferiority trial	64
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial	63
Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study	62
Global prevention of stroke and dementia: the WSO Declaration	61
Sleep disorders in autoimmune encephalitis	61
Towards a treatment for genetic prion disease: trials and biomarkers	60
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial	60
Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions	60
Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care	58
Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments	58
Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment	58
Risks of recurrent stroke and all serious vascular events after spontaneous intracerebral haemorrhage: pooled analyses of two population-based studies	54
Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohor	54
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, pha	53
The role of manganese dysregulation in neurological disease: emerging evidence	52
Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study	51
Spontaneous intracranial hypotension: searching for the CSF leak	51
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, pl	51
Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands (PASSIoN): a first-in-human, open-label intervention study	51
Antipsychotic prescribing to people with dementia during COVID-19	50
Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment	50
Dreams and nightmares in healthy adults and in patients with sleep and neurological disorders	49
Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours	49
Sleep function: an evolutionary perspective	49
Ageing and multiple sclerosis	49
Long COVID: understanding the neurological effects	48
Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study	48
Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial	48
Prehospital stroke management in the thrombectomy era	47
Thrombolysis for acute ischaemic stroke: current status and future perspectives	47
Casemix, management, and mortality of patients receiving emergency neurosurgery for traumatic brain injury in the Global Neurotrauma Outcomes Study: a prospective observational cohort study	47
Management of atherosclerotic extracranial carotid artery stenosis	46
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro	46
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study	46
Cognitive-motor dissociation and time to functional recovery in patients with acute brain injury in the USA: a prospective observational cohort study	45
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase	44
CDKL5 deficiency disorder: clinical features, diagnosis, and management	44
Potential human transmission of amyloid β pathology: surveillance and risks	44
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 tr	44
Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 tri	44

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study	43
COVID-19 and selective vulnerability to Parkinson's disease	43
Diagnosis and treatment of orthostatic hypotension	43
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study	43
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phas	43
Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial	42
Sleep apnoea and ischaemic stroke: current knowledge and future directions	42
Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies	42
Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study	41
Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders	41
Fluid balance and outcome in critically ill patients with traumatic brain injury (CENTER-TBI and OzENTER-TBI): a prospective, multicentre, comparative effectiveness study	41
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial	41
Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study	40
Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: evaluation of a first-in-human treatment programme	39
Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study	39
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial	39
Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis: 5-year results of a multicentre, randomised controlled trial	39
Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial	38
Development of imaging-based risk scores for prediction of intracranial haemorrhage and ischaemic stroke in patients taking antithrombotic therapy after ischaemic stroke or transient ischaemic attack:	38
Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial	37
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial	37
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study	37
Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders	36
Emerging therapies for Duchenne muscular dystrophy	36
Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke	34
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial	34
Effect of frailty on 6-month outcome after traumatic brain injury: a multicentre cohort study with external validation	34
Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development	34
Associations between lifestyle and amyotrophic lateral sclerosis stratified by C9orf72 genotype: a longitudinal, population-based, case-control study	33
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study	33
Intraoperative electrocorticography using high-frequency oscillations or spikes to tailor epilepsy surgery in the Netherlands (the HFO trial): a randomised, single-blind, adaptive non-inferiority tria	33
Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy	33
Sleep research in 2020: COVID-19-related sleep disorders	33
Parkinson's disease outside the brain: targeting the autonomic nervous system	32
Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy	31
Tuberculous meningitis: progress and remaining questions	31
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study	31
Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crosso	31
Intracerebral haemorrhage expansion: definitions, predictors, and prevention	29
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial	29
The role of diet in secondary stroke prevention	29
Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study	28
Personalised virtual brain models in epilepsy	28
Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority tr	27
Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders	27
Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness study	27
Heart health meets cognitive health: evidence on the role of blood pressure	27
Drug resistance in epilepsy	27
Genetics of multiple sclerosis: lessons from polygenicity	26
Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group,	26
Research priorities to improve stroke outcomes	26
Traumatic brain injury as a chronic disease: insights from the United States Traumatic Brain Injury Model Systems Research Program	26
Guillain-Barré syndrome after vaccination against COVID-19	26
Safety and efficacy of occipital nerve stimulation for attack prevention in medically intractable chronic cluster headache (ICON): a randomised, double-blind, multicentre, phase 3, electrical dose-con	26
Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission	26
Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study	25
NeuroCOVID: it's time to join forces globally	25
Chronic remote ischaemic conditioning in patients with symptomatic intracranial atherosclerotic stenosis (the RICA trial): a multicentre, randomised, double-blind sham-controlled trial in China	25
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial	25
Understanding the molecular basis and pathogenesis of hereditary optic neuropathies: towards improved diagnosis and management	24
Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial	24
BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study	24
The neurological impact of COVID-19	23
A call for a global COVID-19 Neuro Research Coalition	22
Family planning considerations in people with multiple sclerosis	22
Imaging of the optic nerve: technological advances and future prospects	22
COVID-19 in older people with cognitive impairment in Latin America	22
A new definition of brain health	22
Progression of cerebral amyloid angiopathy: a pathophysiological framework	21
Lifestyle factors and migraine	21
Towards understanding the effects of spaceflight on the brain	20
Social media could address the gender gap in neurosurgery	20
The necessity of diplomacy in brain health	20
Advances in Alzheimer's disease research over the past two decades	20
Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study	20
Wearable-based mobility monitoring: the long road ahead	19
Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3	19
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research	18
Diagnostic criteria for autoimmune encephalitis: utility and pitfalls for antibody-negative disease	18
Freezing of gait before the introduction of levodopa	18
New hope for advancing neuropalliative care	17
WHO launches its Global Action Plan for brain health	17
Tourette syndrome: clinical features, pathophysiology, and treatment	17
Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial	17
Multiple sclerosis under the spotlight	17
Carpal tunnel syndrome: updated evidence and new questions	17
Brain network reorganisation in an adolescent after bilateral perinatal strokes	16
Multiple sclerosis: two decades of progress	16
The mechanisms of smell loss after SARS-CoV-2 infection	16
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria	16
Off-label use of aducanumab for cerebral amyloid angiopathy	16
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial	16
Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study	15
Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial	15
Movement disorders research in 2021: cracking the paradigm	15